跳到正文
原文
STAT Pharma 医药频道· Jason Mast and Elaine Chen·· 28 天前AI 评分42

Alnylam亨廷顿氏病药物brezosiran早期研究显示有望沉默突变基因

STAT+: Alnylam says Huntington’s drug shows promise in early study

AI 导读

Alnylam Pharmaceuticals表示,其实验性亨廷顿氏病药物brezosiran在小规模早期研究中显示出前景,表明该药能部分沉默导致该神经退行性疾病的突变基因。接受最高剂量患者脊髓液中突变蛋白平均下降60%或64%,安全性“令人鼓舞”。公司计划明年启动安慰剂对照试验以验证其延缓疾病进展的能力。

正文

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.

An experimental Huntington’s drug from Alnylam Pharmaceuticals showed promise in a small study, the company said Friday, suggesting it can partially silence the mutant gene that drives the devastating neurological disorder.

Patients who received the highest dose of the drug, called brezosiran, saw the levels of mutant huntingtin in their spinal fluid fall by 60% or 64% on average, depending on the type of assay used. The company described the safety profile as “encouraging” and said it planned to start a placebo-controlled study next year to prove the drug can actually slow the disease.

“We’re getting high levels of knockdown with good safety and tolerability, and so this is all very, very encouraging,” said Pushkal Garg, head of research and development at Alnylam, which presented the data Friday at the European Huntington’s Disease Network Clinical Research Congress.

STAT+ Exclusive Story

Already have an account? Log in

STAT+

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

来源:STAT Pharma 医药频道 · statnews.com